- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe myoclonic epilepsy in infancy (Dravet syndrome)
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Cannabidiol – March 2026
Oral liquid 100 mg per mL, 100 mL
Last updated
11 March 2026